Get the latest tech news
Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
“I’m sure someone’s lost their job,” said the CEO of Sandoz, which has now filed to launch a generic GLP-1 drug in Canada next year.
The pharma giant will lose its patent protection on semaglutide, which is sold as Ozempic and Wegovy, in Canada after not paying a nominal maintenance fee years before it became a blockbuster drug for fighting diabetes and obesity, Science reported. Years before semaglutide became a blockbuster drug for Novo Nordisk, the Danish pharma giant had the chance to maintain its patent in Canada but didn’t pay a small fee to do so, according to a recent report in Science. In a statement to Fortune, Novo Nordisk said there was no mistake regarding its patent maintenance fee in Canada and declined to comment on other drug manufacturers’ plans.
Or read this on r/technology
